anti-PD-L1 monoclonal antibody (Mayo Clinic Cancer Center)

N/A

Report date: 2025/06/11 10:21:06

Base Information

Drug Nameanti-PD-L1 monoclonal antibody (Mayo Clinic Cancer Center)
Drug Alias NamePD-L1 checkpoint inhibitor (Mayo Clinic Cancer Center)H1A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockersImmunostimulantsT lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsCarcinoma, Renal CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesMayo Clinic
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A